|Dr. Peter M. Hecht||CEO & Director||110.78k||N/A||1964|
|Dr. Andreas Busch Ph.D.||Chief Scientific Officer||662.42k||N/A||1963|
|Ms. Anjeza Gjino||CFO & Corp. Sec.||N/A||N/A||1983|
|Ms. Cheryl Gault||Chief Operating Officer||N/A||N/A||1979|
|Dr. Todd Milne Ph.D.||VP of Corp. Devel.||N/A||N/A||N/A|
|Ms. Jessica Rennekamp||Associate Director of Corp. Communications||N/A||N/A||N/A|
|Mr. Christopher Winrow||Sr. Director of Clinical Devel. & Neuroscience Program Lead||N/A||N/A||N/A|
|Ms. Jennifer Chickering||Sr. Director of Clinical Strategy||N/A||N/A||N/A|
Cyclerion Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovering, development, and commercialization of medicines for serious central nervous system (CNS) diseases. Its product candidates include CY6463, a CNS-penetrant, soluble guanylate cyclase (sGC) stimulator that is in Phase II trials for the treatment of mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes (MELAS) and Alzheimer's disease with vascular pathology (ADv); Olinciguat, an orally administered vascular soluble guanylate cyclase stimulator that is in Phase II studies for the treatment of sickle cell disease (SCD); Praliciguat, an orally administered systemic sGC stimulator that is in Phase II trials for the treatment of diabetic nephropathy and heart failure with preserved ejection fraction. The company was incorporated in 2018 and is headquartered in Cambridge, Massachusetts.
Cyclerion Therapeutics, Inc.’s ISS governance QualityScore as of 1 July 2021 is 3. The pillar scores are Audit: 3; Board: 4; Shareholder rights: 2; Compensation: 7.